The role of physical training in correcting metabolic inflammation parameters, body structure indices and vascular wall stiffness in patients with arterial hypertension in the post-COVID period
Perm Medical Journal · 10.07.2026 · 43 (3) · 139-151
DOI: 10.17816/pmj433139-151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Perm Medical Journal, online erschienen am 10.07.2026. Verfasst von K. S. Avdeeva und 4 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Objective
To study the impact of regular physical exercise on the dynamics of systemic metabolic inflammation biomarkers, body composition indices, muscle mass, and vascular elasticity parameters in patients with arterial hypertension who recovered from COVID-19. Materials and methods. This single-center prospective interventional study included 74 patients with hypertension 3 months after recovering from COVID-19. The study group (n = 37) performed an adapted exercise therapy program (3 gym sessions and 4 home workouts per week) for 9 months in addition to standard recommendations; the control group (n = 37) received only standard recommendations. The following parameters were assessed at baseline and after 9 months: inflammatory markers (IL-1b, IL-6, IL-10, TNF-a, CRP), lipid profile, glycemic control (HbA1c, TyG, CTI, TyG-WHtR), metabolic indices of body structure, muscle strength parameters (deadlift strength), body composition (bioelectrical impedance analysis), 24-hour blood pressure monitoring (ABPM) parameters, and pulse wave velocity (PWV).
Results
In the exercise therapy group, a significant decrease in proinflammatory cytokines IL-1b by 28.7 % (p = 0.028) and TNF-a by 31.2 % (p = 0.011) was recorded, with an increase in anti-inflammatory IL-10 by 20.0 % (p = 0.001); HbA1c decreased to 5.38 % (p = 0.010), TyG-WHtR by 10.7 % (p = 0.003). A decrease in waist circumference by 9.4 cm (p = 0.001), BMI by 2.7 kg/m2 (p = 0.001), and waist-to-hip ratio (WHR) (p = 0.020) was revealed; deadlift strength increased by 16.3 % (p = 0.002) with a decrease in absolute fat mass by 4.36 kg (p = 0.001) according to bioelectrical impedance analysis. According to ABPM, in the exercise therapy group there was a decrease in the diastolic blood pressure (DBP) variability (p = 0.021), the rate-pressure product (p = 0.050) and night HR (p = 0.034) compared to the control. The PWV indicator decreased by 11 %, but did not reach the target values.
Conclusions
A long-term regular physical training program in patients with hypertension in the post-COVID period improves structural and functional parameters of the body and muscle function, while reducing markers of metabolic inflammation, improving hemodynamic parameters, and improving vascular elasticity. These data support the inclusion of moderate-intensity physical training in the treatment and prevention program for this patient population.
Zitieren
APA
Avdeeva, K. S., Petelina, T. I., Vasilkova, T. N., Nikiforova, Y. A., & Sharoyan, Y. A. (2026). The role of physical training in correcting metabolic inflammation parameters, body structure indices and vascular wall stiffness in patients with arterial hypertension in the post-COVID period. Perm Medical Journal, 43(3), 139-151. https://doi.org/10.17816/pmj433139-151
Vancouver
Avdeeva KS, Petelina TI, Vasilkova TN, Nikiforova YA, Sharoyan YA. The role of physical training in correcting metabolic inflammation parameters, body structure indices and vascular wall stiffness in patients with arterial hypertension in the post-COVID period. Perm Medical Journal. 2026;43(3):139-151. doi:10.17816/pmj433139-151
BibTeX
@article{Avdeeva2026,
author = {Avdeeva, K. S. and Petelina, T. I. and Vasilkova, T. N. and Nikiforova, Y. A. and Sharoyan, Y. A.},
title = {The role of physical training in correcting metabolic inflammation parameters, body structure indices and vascular wall stiffness in patients with arterial hypertension in the post-COVID period},
journal = {Perm Medical Journal},
year = {2026},
volume = {43},
number = {3},
pages = {139--151},
doi = {10.17816/pmj433139-151}
}
EUVIMED